Amgen (AMGN) Competitors

$273.54
+1.63 (+0.60%)
(As of 04/23/2024 ET)

AMGN vs. GILD, MRNA, PFE, ISRG, SYK, ELV, SNY, MDT, VRTX, and CI

Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Moderna (MRNA), Pfizer (PFE), Intuitive Surgical (ISRG), Stryker (SYK), Elevance Health (ELV), Sanofi (SNY), Medtronic (MDT), Vertex Pharmaceuticals (VRTX), and The Cigna Group (CI). These companies are all part of the "medical" sector.

Amgen vs.

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk.

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$27.12B3.08$5.67B$4.5014.90
Amgen$28.19B5.20$6.72B$12.4921.90

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by insiders. Comparatively, 0.6% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Gilead Sciences presently has a consensus price target of $84.71, indicating a potential upside of 26.38%. Amgen has a consensus price target of $296.95, indicating a potential upside of 8.56%. Given Amgen's higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilead Sciences
1 Sell rating(s)
9 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.27
Amgen
0 Sell rating(s)
9 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.53

Gilead Sciences pays an annual dividend of $3.08 per share and has a dividend yield of 4.6%. Amgen pays an annual dividend of $9.00 per share and has a dividend yield of 3.3%. Gilead Sciences pays out 68.4% of its earnings in the form of a dividend. Amgen pays out 72.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 9 consecutive years and Amgen has raised its dividend for 12 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Amgen had 9 more articles in the media than Gilead Sciences. MarketBeat recorded 33 mentions for Amgen and 24 mentions for Gilead Sciences. Amgen's average media sentiment score of 0.44 beat Gilead Sciences' score of 0.23 indicating that Gilead Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gilead Sciences
10 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
6 Negative mention(s)
1 Very Negative mention(s)
Neutral
Amgen
12 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral

Amgen has a net margin of 23.83% compared to Amgen's net margin of 20.89%. Gilead Sciences' return on equity of 154.27% beat Amgen's return on equity.

Company Net Margins Return on Equity Return on Assets
Gilead Sciences20.89% 38.85% 13.60%
Amgen 23.83%154.27%10.95%

Gilead Sciences has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Gilead Sciences received 924 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 77.47% of users gave Gilead Sciences an outperform vote while only 72.50% of users gave Amgen an outperform vote.

CompanyUnderperformOutperform
Gilead SciencesOutperform Votes
2445
77.47%
Underperform Votes
711
22.53%
AmgenOutperform Votes
1521
72.50%
Underperform Votes
577
27.50%

Summary

Amgen beats Gilead Sciences on 13 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMGN vs. The Competition

MetricAmgenBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$146.72B$2.60B$4.84B$7.49B
Dividend Yield3.35%2.89%5.51%3.98%
P/E Ratio21.9047.47240.8920.93
Price / Sales5.20311.512,419.7589.75
Price / Cash10.20150.0132.1727.25
Price / Book23.483.944.684.31
Net Income$6.72B-$49.09M$102.52M$213.83M
7 Day Performance3.59%-0.33%0.41%1.35%
1 Month Performance-0.95%-9.67%-5.79%-4.08%
1 Year Performance11.90%5.99%10.14%7.92%

Amgen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GILD
Gilead Sciences
4.9983 of 5 stars
$67.31
-0.6%
$85.36
+26.8%
-22.6%$83.81B$27.12B14.9618,000Upcoming Earnings
Analyst Revision
MRNA
Moderna
3.9617 of 5 stars
$103.79
-0.1%
$126.49
+21.9%
-23.4%$39.74B$6.85B-8.365,600
PFE
Pfizer
4.995 of 5 stars
$25.69
-0.8%
$36.88
+43.5%
-34.5%$145.47B$58.50B71.3688,000Upcoming Earnings
ISRG
Intuitive Surgical
4.6837 of 5 stars
$378.55
+0.3%
$375.70
-0.8%
+25.6%$134.18B$7.12B75.2613,676Earnings Report
SYK
Stryker
4.7936 of 5 stars
$337.54
-0.5%
$339.22
+0.5%
+10.3%$128.42B$20.50B40.9152,000Upcoming Earnings
ELV
Elevance Health
4.8389 of 5 stars
$507.02
+1.4%
$569.00
+12.2%
+18.2%$117.98B$171.34B20.14104,900Earnings Report
Dividend Announcement
Analyst Revision
SNY
Sanofi
3.0729 of 5 stars
$45.80
-1.0%
$55.00
+20.1%
-15.9%$115.86B$46.61B19.4186,088Upcoming Earnings
MDT
Medtronic
4.5979 of 5 stars
$79.25
-1.2%
$94.91
+19.8%
-5.2%$105.23B$31.23B25.2495,000
VRTX
Vertex Pharmaceuticals
4.3631 of 5 stars
$394.17
-0.8%
$424.62
+7.7%
+22.3%$101.88B$9.87B28.385,400Analyst Revision
CI
The Cigna Group
4.787 of 5 stars
$346.79
-0.6%
$362.14
+4.4%
+39.9%$101.39B$195.27B19.9472,500

Related Companies and Tools

This page (NASDAQ:AMGN) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners